Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?
- PMID: 22571169
- PMCID: PMC4015798
- DOI: 10.1056/NEJMp1202623
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?
References
-
- Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. 2011 Sep 9; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria....
-
- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38. - PubMed
-
- Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25:976–82. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical